Pancreatic Cancer Patients Find Promising Treatment That Diminishes Tumor Size

By: Peter Kent

Pancreatic Cancer Patients Find Promising Treatment That Diminishes Tumor Size

The University of Colorado Hospital has recently embarked on what news reports have deemed a "groundbreaking medical trial" for patients suffering from pancreatic cancer. The trial uses a new technique designed to "shrink the tumor with very concentrated, very localized medication," according to 7 Denver News, a local television news casting station.

Physicians have been using a combination of the drug known as Tumor Necrosis Factor along with Imaged Guided Radiation Therapy technology. The therapy works in two phases, with the first phase administered each week as "doctors use an endoscope through the mouth to the stomach to deliver the drug and inject it directly into the tumor," reported 7 Denver News. In the second phase, the tumor, which is now drug-filled, is subject to a daily blast of radiation, which attempts to stimulate the drug until the tumor begins to break down.

While the trial continues to be conducted, physicians with the study have already noted that, "patients with the standard treatment survive about eight-and-a-half months and that patients with this new treatment live about eleven-and-a-half months."

Pancreatic Cancer Signs and Symptoms

Pancreatic cancer occurs when cancerous cells "begin in the ducts of the pancreas, but they sometimes develop from the cells of that make the pancreatic enzymes," according to the American Cancer Society (ACS). The Mayo Clinic also explained that there are several signs and symptoms of the pancreatic cancer including the following:

* loss of appetite

* depression

* weight loss

* yellowing of the skin

* yellowing of the whites of the eyes

* upper abdominal pain


There are a number of reasons that pancreatic cancer can occur, however, one of the most recent risks is that of Byetta consumption.

Byetta is a type 2 diabetes drug that is prescribed to patients as an injectable form of insulin to regulate glucose levels in individuals. The drug was released in 2005 from Amylin Pharmaceuticals and Eli Lilly and Company. Recently, the drug was linked to the onset of pancreatitis, which can develop into pancreatic cancer if left untreated.

In 2008, approximately six patients were hospitalized for their Byetta-induced side effects of acute pancreatitis. Of the six patients, two resulted in fatality. Patients who have experienced the Byetta dangers are advised to discuss their case with a pharmaceutical attorney who can offer a free legal consultation as to the development of a Byetta class action lawsuit, which may result in the reward of monetary funds for a Byetta patient.

Peter Kent is the best-selling author of 50 books and hundreds of articles for magazines and newspapers. He manages Legalview.info, a website hosting a variety of information on legal issues, including Byetta.

Article Source: http://www.ArticleBiz.com